May 27, 2021 10:38 AM EDTUpdated 11:50 AM
News Briefing

Astel­las out­lines an­oth­er five-year plan; Bay­er's VC arm leaps in­to dig­i­tal health

Jason Mast

Editor

Three years af­ter Astel­las un­veiled its last five-year plan, the Japan­ese phar­ma is un­veil­ing an­oth­er.

The new blue­print, an­nounced Wednes­day, is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times